Aiming Low On Product Recalls Draws FDA Concern – Experts
This article was originally published in The Tan Sheet
Executive Summary
Drug and supplement firms should prepare detailed recall strategies and should not aim low on product volume when they conduct recalls, according to an FDA official and an industry consultant